Brandenburg Kapital - News about SphingoTec GmbH
SphingoTec and Beckman Coulter Partner to Improve Kidney Health Assessment in Critical Care
Hennigsdorf – October 2024. Diagnostic company SphingoTec GmbH (“SphingoTec”) today announced a new licensing partnership with Beckman Coulter Diagnostics Inc. (“Beckman Coulter”). Through this collaboration, the companies will bring an assay for SphingoTec’s innovative kidney function biomarker, Proenkephalin 119-159 (penKid), to Beckman Coulter’s extensive test menu for use on the Access Family of Immunoassay Analyzers. This alliance marks the first central laboratory license for a penKid assay and aims to significantly enhance the diagnostic capabilities for acute kidney injury (AKI) globally, by leveraging Beckman Coulter’s global installed base of instruments.
Scientific studies have shown that penKid offers a faster detection of kidney function decline and thus allows for an earlier treatment decision by critical care physicians.
SphingoTec develops and markets innovative in-vitro-diagnostic solutions for novel biomarkers for intensive care. The biomarkers provide important, organ-specific information for monitoring acute disease progressions such as sepsis or acute renal failure. In doing so, they support clinical decisions with the aim of improving patient care and management.
Brandenburg Kapital GmbH has been supporting the company since 2018.
Read the full press release here:.
For more information, please visit: www.brandenburg-kapital.de, www.sphingotec.com